Movement Alert｜Corcept Therapeutics Rises 18.34% in After-Hours Trading, Q2 Earnings Significantly Beat Expectations

Market Focus

Jul 30

On July 30, Corcept Therapeutics rose 18.34% in after-hours trading, trading at $110.08/share, with turnover of $8.8785 million.

The surge was driven by the company's Q2 earnings release, which massively exceeded market expectations. Corcept reported earnings per share of $0.36, far surpassing the analyst consensus estimate of $0.00, representing a 24.14% year-over-year increase from $0.29 per share in the prior-year period. Revenue came in at $256.147 million, beating the Street estimate of $219.988 million by approximately 16.4%.

The strong outperformance was primarily attributed to the continued commercial momentum of its core product Korlym and the successful commercialization of newly approved drug Lifyorli. Additionally, the company resubmitted its New Drug Application for Relacorilant for the treatment of Cushing's syndrome in June, with multiple pipeline programs advancing smoothly, further boosting investor confidence in the company's growth trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1127100880"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1127100880\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1127100880?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 04:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127100880","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Corcept Therapeutics Rises 18.34% in After-Hours Trading, Q2 Earnings Significantly Beat Expectations","media":"Market Focus","content":"<p><p>On July 30, Corcept Therapeutics rose 18.34% in after-hours trading, trading at $110.08/share, with turnover of $8.8785 million.</p><p>The surge was driven by the company's Q2 earnings release, which massively exceeded market expectations. Corcept reported earnings per share of $0.36, far surpassing the analyst consensus estimate of $0.00, representing a 24.14% year-over-year increase from $0.29 per share in the prior-year period. Revenue came in at $256.147 million, beating the Street estimate of $219.988 million by approximately 16.4%.</p><p>The strong outperformance was primarily attributed to the continued commercial momentum of its core product Korlym and the successful commercialization of newly approved drug Lifyorli. Additionally, the company resubmitted its New Drug Application for Relacorilant for the treatment of Cushing's syndrome in June, with multiple pipeline programs advancing smoothly, further boosting investor confidence in the company's growth trajectory.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Corcept Therapeutics Rises 18.34% in After-Hours Trading, Q2 Earnings Significantly Beat Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Corcept Therapeutics Rises 18.34% in After-Hours Trading, Q2 Earnings Significantly Beat Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-30 04:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 30, Corcept Therapeutics rose 18.34% in after-hours trading, trading at $110.08/share, with turnover of $8.8785 million.</p><p>The surge was driven by the company's Q2 earnings release, which massively exceeded market expectations. Corcept reported earnings per share of $0.36, far surpassing the analyst consensus estimate of $0.00, representing a 24.14% year-over-year increase from $0.29 per share in the prior-year period. Revenue came in at $256.147 million, beating the Street estimate of $219.988 million by approximately 16.4%.</p><p>The strong outperformance was primarily attributed to the continued commercial momentum of its core product Korlym and the successful commercialization of newly approved drug Lifyorli. Additionally, the company resubmitted its New Drug Application for Relacorilant for the treatment of Cushing's syndrome in June, with multiple pipeline programs advancing smoothly, further boosting investor confidence in the company's growth trajectory.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CORT","symbol_name":"Corcept医疗","start_time":0,"source_url":"","article_id":"1127100880","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127100880","pubTimestamp":1785357069,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 30, Corcept Therapeutics rose 18.34% in after-hours trading, trading at $110.08/share, with turnover of $8.8785 million.The surge was driven by the company's Q2 earnings release, which...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CORT":"Corcept医疗"},"translate_title":"走势提醒|Corcept Therapeutics 盘后交易上涨 18.34%，第二季度盈利大幅超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":1},"content_text":"On July 30, Corcept Therapeutics rose 18.34% in after-hours trading, trading at $110.08/share, with turnover of $8.8785 million.The surge was driven by the company's Q2 earnings release, which massively exceeded market expectations. Corcept reported earnings per share of $0.36, far surpassing the analyst consensus estimate of $0.00, representing a 24.14% year-over-year increase from $0.29 per share in the prior-year period. Revenue came in at $256.147 million, beating the Street estimate of $219.988 million by approximately 16.4%.The strong outperformance was primarily attributed to the continued commercial momentum of its core product Korlym and the successful commercialization of newly approved drug Lifyorli. Additionally, the company resubmitted its New Drug Application for Relacorilant for the treatment of Cushing's syndrome in June, with multiple pipeline programs advancing smoothly, further boosting investor confidence in the company's growth trajectory.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}